Policy implications of integrating buprenorphine/naloxone treatment and HIV care

Journal of Acquired Immune Deficiency Syndromes

Volumn 56, Issue SUPPL. 1, 2011, Pages

  Finkelstein, Ruth ^a   Netherland, Julie ^a   Sylla, Laurie ^b   Gourevitch, Marc N ^c   Cajina, Adan ^d   Cheever, Laura ^d  

^a NEW YORK ACADEMY OF MEDICINE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d HEALTH RESOURCES AND SERVICES ADMINISTRATION   (United States)

Author keywords

buprenorphine naloxone; HIV AIDS; opioid treatment; policy; substance use treatment

Indexed keywords

BUPRENORPHINE PLUS NALOXONE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADDICTION; ARTICLE; CROSS TRAINING; DRUG EFFICACY; HEALTH CARE FINANCING; HEALTH CARE POLICY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL CARE; MEDICAL EDUCATION; PHYSICIAN; PRIORITY JOURNAL; REIMBURSEMENT;

BUPRENORPHINE; DELIVERY OF HEALTH CARE, INTEGRATED; HEALTH POLICY; HIV INFECTIONS; HUMANS; NALOXONE; NARCOTIC ANTAGONISTS; OPIATE SUBSTITUTION TREATMENT; UNITED STATES;

EID: 79951792248     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31820a9a97     Document Type: Article

References (53)

1. Willenbring ML, Olson DH. A randomized trial of integrated outpatient treatment for medically ill alcoholic men. Arch Intern Med. 1999;159: 1946-1952. (Pubitemid 29424716)
2. Fiellin DA, Rosenheck RA, Kosten TR. Office-based treatment for opioid dependence: reaching new patient populations. Am J Psychiatry. 2001; 158:1200-1204. (Pubitemid 32717691)
3. Weisner C, Mertens J, Parthasarathy S, et al. Integrating primary medical care with addiction treatment: a randomized controlled trial. JAMA. 2001; 286:1715-1723. (Pubitemid 33010257)
4. Merrill JO. Policy progress for physician treatment of opiate addiction. J Gen Intern Med. 2002;17:361-368. (Pubitemid 34626105)
5. Lago M, Levin S, Pharham D. Linkage solutions between primary care, HIV/AIDS, substance abuse and mental health services in nongovernmental health care organizations. Paper presented at: International AIDS Conference; 1998; Geneva, Switzerland.
6. Samet JH, Friedmann P, Saitz R. Benefits of linking primary medical care and substance abuse services: patient, provider, and societal perspectives. Arch Intern Med. 2001;161:85-91. (Pubitemid 32052147)
7. Rhoades H, Creson D, Elk R, et al. Retention, HIV risk and illicit drug use during treatment: methadone dose and visit frequency. Am J Pub Health. 1998;88:34-39. (Pubitemid 28109638)
8. Weinrich M, Stuart M. Provision of methadone treatment in primary care medical practices: review of the Scottish experience and implications for US policy. JAMA. 2000;283:1343-1348. (Pubitemid 30129806)
9. King VL, Stoller KB, Hayes M, et al. A multicenter randomized evaluation of methadone medical maintenance. Drug Alcohol Depend. 2002;65:137-148. (Pubitemid 34084897)
10. Novick DM, Joseph H. Medical maintenance: the treatment of chronic opiate dependence in general medical practice. J Subst Abuse Treat. 1991; 8:233-239.
11. Gossop M, Marsden J, Stewart D, et al. Methadone treatment practices and outcome for opiate addicts treated in drug clinics and in general practice: results from the National Treatment Outcome Research Study. Br J Gen Pract. 1999;49:31-34. (Pubitemid 29027498)
12. Keen J, Oliver P, Rowse G, et al. Does methadone maintenance treatment based on the new national guidelines work in a primary care setting? Br J Gen Pract. 2003;53:461-467. (Pubitemid 36740612)
13. Wilson P, Watson R, Ralston GE. Methadone maintenance in general practice: patients, workload, and outcomes. BMJ. 1994;309:641-644. (Pubitemid 24281184)
14. Novick DM, Joseph H, Salsitz EA, et al. Outcomes of treatment of socially rehabilitated methadone maintenance patients in physicians' offices (medical maintenance): follow-up at three and a half to nine and a fourth years. J Gen Intern Med. 1994; 9:127-130. (Pubitemid 24114745)
15. Fiellin DA, O'Connor PG, Chawarski M, et al. Methadone maintenance in primary care: a randomized controlled trial. JAMA. 2001;286:1724-1731. (Pubitemid 33010258)
16. Miller NS, Sheppard LM, Colenda CC, et al. Why physicians are unprepared to treat patients who have alcohol- and drug-related disorders. Acad Med. 2001;76:410-418. (Pubitemid 32417323)
17. Missed Opportunity: National Survey of Primary are Physicians and Patients on Substance Abuse. New York, NY: Center On Addiction and Substance Abuse; April 2000.
18. Position Paper on Drug Policy. Providence, RI: Physician Leadership on National Drug Control Policy; January 2000.
19. Gerbert B, Maguire BT, Bleecker T, et al. Primary care physicians and AIDS: attitudinal and structural barriers to care. JAMA. 1991;266: 2837-2842.
20. Merrill JO, Rhodes LA, Deyo RA, et al. Mutual mistrust in the medical care of drug users: the keys to the "narc" cabinet. J Gen Intern Med. 2002; 17:327-333. (Pubitemid 34626100)
21. Moatti JP, Souville M, Escaffre N, et al. French general practitioners' attitudes toward maintenance drug abuse treatment with buprenorphine. Addiction. 1998;93:1567-1575. (Pubitemid 28472997)
22. Saitz R, Horton NJ, Sullivan LM, et al. Addressing alcohol problems in primary care: a cluster randomized, controlled trial of a systems intervention. The screening and intervention in primary care (SIP) study. Ann Intern Med. 2003;138:372-382. (Pubitemid 36262647)
23. Erickson CK, Wilcox RE, Miller GW, et al. Effectiveness of addiction science presentations to treatment professionals, using a modified Solomon study design. J Drug Educ. 2003;33:197-216. (Pubitemid 36935941)
24. Christison GW, Haviland MG. Requiring a one-week addiction treatment experience in a six-week psychiatry clerkship: effects on attitudes toward substance-abusing patients. Teach Learn Med. 2003;15:93-97. (Pubitemid 37026172)
25. Karam-Hage M, Nerenberg L, Brower KJ. Modifying residents' professional attitudes about substance abuse treatment and training. Am J Addict. 2001;10:40-47. (Pubitemid 32201732)
26. Fiellin DA, O'Connor P, Chawarski M, et al. Process of care during a randomized trial of office-based treatment of opioid dependence in primary care. Am J Addict. 2004;13(Suppl 1):S67-S78. (Pubitemid 38585691)
27. Elliott V. Link between primary care, addiction services may help treatment. amednews.com. 2001.
28. Tobias C, Drainoni M.Title I Survey: Services for HIV Positive Substance Users. Boston, MA: Heatlh and Disability Working Group, Boston University School of Public Health; September 8, 2001.
29. Mantell J, Cassidy T. Unpublished Data From 100 Interviews With Patients in HIV Medication Adherence Programs Across the US. New York, NY: The New York Academy of Medicine; 2001.
30. Weiss L, Kluger M, McCoy K. Health Care Accessibility and Acceptability Among People That Inject Drugs or Use Crack Cocaine. New York City, NY: Office of Special Populations, The New York Academy of Medicine; 2000.
31. Stancliff S, Myers J, Steiner S, et al. Beliefs about methadone in an inner-city methadone clinic. J Urban Health. 2002;79:571-578. (Pubitemid 36076530)
32. Weiss L, Egan J, Botsko M, et al. A multi-site evaluation of integrated buprenorphine/naloxone and HIV treatment: overview of the BHIVES collaborative. J Acquir Immune Defic Syndr. 2011;56(Suppl 1):S1-S2.
33. Netherland J, Botsko M, Egan JE, et al. Factors affecting willingness to provide buprenorphine treatment. J Subst Abuse Treat. 2009;36:244-251.
34. Becker WC, Fiellin DA, Merrill JO, et al. Opioid use disorder in the United States: insurance status and treatment access. Drug Alcohol Depend. 2008;94:207-213.
35. Horgan CM, Reif S, Hodgkin D, et al. Availability of addiction medications in private health plans. J Subst Abuse Treat. 2008;34:147-156. (Pubitemid 351163511)
36. ADAP criteria and formularies. 2010. Available at: www.hivpositivema- gazine.com/adap.html. Accessed July 30, 2010.
37. National ADAP Monitoring Project Annual Report. 2009. Available at: http://www.kff.org/hivaids/7861.cfm. Accessed July 30, 2010.
38. Schackman B, Leff J, Botsko M, et al. The cost of integrated HIV care and buprenorphine/naloxone treatment: results of a cross-site evaluation. J Acquir Immune Defic Syndr. 2011;56(Suppl 1):S76-S82.
39. Jones ES, Moore BA, Sindelar JL, et al. Cost analysis of clinic and office-based treatment of opioid dependence: results with methadone and buprenorphine in clinically stable patients. Drug Alcohol Depend. 2009; 99:132-140.
40. Zarkin GA, Dunlap LJ, Homsi G. The substance abuse services cost analysis program (SASCAP): a new method for estimating drug treatment services costs. Eval Program Plann. 2004;27:35-43. (Pubitemid 37551534)
41. Woody GE, Poole SA, Subramaniam G, et al. Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial. JAMA. 2008;300:2003-2011.
42. Kakko J, Svanborg KD, Kreek MJ, et al. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. Lancet. 2003;361:662-668. (Pubitemid 36246548)
43. Sees KL, Delucchi KL, Masson C, et al. Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence: a randomized controlled trial. JAMA. 2000;283:1303-1310. (Pubitemid 30129797)
44. Lum P, Little S, Botsko M, et al. Opioid prescribing and provider confidence recognizing opioid abuse in HIV primary care settings. J Acquir Immune Defic Syndr. 2011;56(Suppl 1):S91-S97.
45. Egan J, Casadonte P, Gartenmann T, et al. The physician clinical support system-buprenorphine (PCSS-B): a novel project to expand/improve buprenorphine treatment. J Gen Intern Med. In press.
46. Egan J, Netherland J, Gass J, et al. Patient perspectives on buprenorphine/ naloxone treatment in the context of HIV care. J Acquir Immune Defic Syndr. 2011;56(Suppl 1):S46-S53.
47. Fiellin DA, Sullivan LE, Egan JE, et al. Drug treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone. J Acquir Immune Defic Syndr. 2011;56(Suppl 1):S33-S38.
48. Korthuis P, Fiellin D, Rongwei F, et al. Improving adherence to HIV quality of care indicators in persons with opioid dependence: the role of buprenorphine/naloxone. J Acquir Immune Defic Syndr. 2011;56(Suppl 1): S83-S90.
49. Altice F, Bruce R, Lucas G. HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study. J Acquir Immune Defic Syndr. 2011;56(Suppl 1):S22-S32.
50. Korthuis PT, Tozzi MJ, Nandi V. Improved quality of life for opioid-dependent patients receiving buprenorphine treatment in HIV clinics. J Acquir Immune Defic Syndr. 2011;56(Suppl 1):S39-S45.
51. Chalk M. Financing Buprenorphine in the Treatment of Opioid Addiction. Buprenorphine Summit. Bethseda, MD: CSAT; 2010.
52. Rinaldo D. Medicaid Financing of Medication-Assisted Treatment for Opiate Addiction. Washington, DC: National Conference of State Legislatures; April 1, 2008.
53. Cheever L, Kresina T, Cajina A, et al. A model federal collaborative to increase patient access to buprenorphine treatment in HIV primary care. J Acquir Immune Defic Syndr. 2011;56(Suppl 1):S3-S6.